Literature DB >> 31175463

A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.

Han Han1,2, Yue Zhao1,2, Zhendong Gao1,2, Difan Zheng1,2, Fangqiu Fu1,2, Zitong Zhao1,2, Ya Tang1,2, Jiaqing Xiang1,2, Yihua Sun1,2, Hong Hu1,2, Haiquan Chen3,4.   

Abstract

PURPOSE: The survival of patients with IIIA-N2 non-small cell lung cancer after surgery followed by adjuvant chemotherapy is heterogeneous. The aim of this study is to form a prognostic system and a heat map method to visualize the overall survival rates in those patients.
METHODS: Univariate and multivariate Cox hazards regression models and the associated Wald Chi square coefficient were used to form the prognostic score system. Recursive partitioning analysis was used to determine the cutoff values of lymph node ratio and prognostic score in SEER cohort and validated in FDUSCC cohort. Meanwhile, a heat map method was used to visualize the overall survival probabilities of 3, 5 and 10 years for individual patient of both cohorts.
RESULTS: Lymph node ratio (with cutoff of 0.36) significantly correlates with overall survival of these patients. In addition, in patients with the same level of N2 disease, lymph node ratio still significantly affects survival. Also, after the multivariate analysis in SEER cohort, six factors were independent prognostic factors including age, sex, type of surgery, size, lymph node ratio and differentiation. A prognostic sore system with these factors (with cutoff of 12) was validated as a predictor for overall survival in FDUSCC cohort.
CONCLUSIONS: This prognostic score system including lymph node ratio can predict the survival rates of IIIA-N2 patient after surgery and post-operative chemotherapy. Lymph node ratio could be a useful supplementation in TNM stage classification for IIIA-N2 patients. The heat map method can visualize the predicted overall survival of an individual patient.

Entities:  

Keywords:  Adjuvant chemotherapy; Mediastinal lymph node metastasis; Non-small cell lung cancer; Surgery

Mesh:

Year:  2019        PMID: 31175463     DOI: 10.1007/s00432-019-02952-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  15 in total

1.  Residual-based tree-structured survival analysis.

Authors:  Sündüz Keleş; Mark R Segal
Journal:  Stat Med       Date:  2002-01-30       Impact factor: 2.373

2.  Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.

Authors:  Matthew D Taylor; Damien J LaPar; Christopher J Thomas; Matthew Persinger; Edward B Stelow; Benjamin D Kozower; Christine L Lau; David R Jones
Journal:  Ann Thorac Surg       Date:  2013-08-30       Impact factor: 4.330

3.  Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.

Authors:  Damien Urban; Jair Bar; Benjamin Solomon; David Ball
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

4.  Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer.

Authors:  Chukwumere E Nwogu; Adrienne Groman; Daniel Fahey; Sai Yendamuri; Elisabeth Dexter; Todd L Demmy; Austin Miller; Mary Reid
Journal:  Ann Thorac Surg       Date:  2012-03-20       Impact factor: 4.330

5.  The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma.

Authors:  Yue Zhao; Guodong Li; Difan Zheng; Ming Jia; Weixing Dai; Yihua Sun; Haiquan Chen
Journal:  J Thorac Cardiovasc Surg       Date:  2016-12-15       Impact factor: 5.209

6.  Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

Authors:  Vincent Wai-Sun Wong; Stephen Lam Chan; Frankie Mo; Tung-Ching Chan; Herbert Ho-Fung Loong; Grace Lai-Hung Wong; Yanni Yan-Ni Lui; Anthony Tak-Cheung Chan; Joseph Jao-Yiu Sung; Winnie Yeo; Henry Lik-Yuen Chan; Tony Shu-Kam Mok
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

7.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

Authors:  R Arriagada; A Auperin; S Burdett; J P Higgins; D H Johnson; T Le Chevalier; C Le Pechoux; M K B Parmar; J P Pignon; R L Souhami; R J Stephens; L A Stewart; J F Tierney; H Tribodet; J van Meerbeeck
Journal:  Lancet       Date:  2010-03-24       Impact factor: 79.321

8.  The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.

Authors:  Chen Qiu; Wei Dong; Benhua Su; Qi Liu; Jiajun Du
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

9.  The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer.

Authors:  Valerie W Rusch; Hisao Asamura; Hirokazu Watanabe; Dorothy J Giroux; Ramon Rami-Porta; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-05       Impact factor: 15.609

10.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

View more
  1 in total

1.  Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study.

Authors:  Yue Yu; Peng Zhang; Renqi Yao; Junnan Wang; Pei Wang; Xiaofei Xue; Jian Xiao; Zhinong Wang
Journal:  Transl Lung Cancer Res       Date:  2020-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.